Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: another falling session

February 7, 2020 5:31pm

Most would agree the fundamental situation has been banged around a bit, especially this week of 2 negative versus 3 positive closes with a finance pricing (AGTC), a reverse split (BLCM) and an earnings report (ALNY)

The week’s “numbers” in review

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

The Dow closed DOWN -277.26 points (-0.94%), the S&P closed DOWN -18.07 points (-0.54%) and the NASDAQ closed DOWN -51.64 points (-0.54%)

Henry’omics:

Referring to the title, here is where it gets messy. Intelligence is valuable. Not only to the businesses collecting and acting on it, but also to bad actors who want to steal or corrupt it. When it comes to sector data, the value is too great to ignore – by good guys and bad guys equally. That is why I tell my clients that risks will always grow and always seem a little scary, but not to fear, because every risk is manageable.

Indexes fell on Friday as worries over the coronavirus’ impact on the Chinese economy outweighed the release of stronger-than-expected U.S. jobs data.

All is not bad, as the S&P 500 gained more than 3% week to date, and its best weekly performance since early June. The Dow climbed 3% for the week while the Nasdaq gained 4%.

As I stated in this a.m.’s Data Docket, the U.S. economy added 225,000 jobs in January; economists expected a print of 158,000 jobs. Wages rose 3.1% on a year-over-year basis, also topping expectations.

These past two (2) sessions, we've all experienced "gut churn”! It's that feeling when your stomach stops to function, while you anticipate or wait for something versus anything to happen.

I will say, share pricings are disconnected from fundamentals, as we enter the earnings zone.

Although I am not one who is prone to hyperbole, the upcoming deluge of Q4 earnings and FY2019 announcements has the potential to drive the FY2020 direction for equities - Alnylam Pharmaceuticals (ALNY +$3.52) is an example post earning’s announcement < https://www.regmedinvestors.com/articles/11218 >

Anyone who reads my posts, knows that I am about making money, no matter what happens in the sector.

I answer one question, in which company should investors put, keep and commit their money.

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Friday the IBB closed down -0.94% and XBI closed down -0.83%
Thursday the IBB closed up +0.91% and XBI closed up +0.10%
Wednesday the IBB closed up +3.01% and XBI closed up +2.33%
Tuesday the IBB closed up +2.36% and XBI closed up +2.85%
Monday the IBB closed up+1.77% and XBI closed up +2.24%

The advance/decline line scenario of 35 covered companies:

· Friday the close was negative with an A/D line of 9/26, 0 flats of 35 covered,

· Thursday the close was negative with an A/D line of 12/23, 0 flats of 35 covered,

· Wednesday the close was positive with an A/D line of 27/5, 3 flats of 35 covered,

· Tuesday the close was positive with an A/D line of 30/5, 0 flat of 35 covered,

· Monday the close was positive with an A/D line of 24/8, 3 flats of 35 covered,

Decliners:

· ReNeuron (RENE.L -$3.00 after Thursday’s +$9.00, Wednesday’s +$1.50, Tuesday’s +$5.00 and Monday’s -$7.50);

· uniQure NV (QURE -$2.06 after Thursday’s -$1.01) and Wednesday’s +$2.30);

· CRISPER Therapeutics (CRSP -$2.01);

· Editas Medicine (EDIT -$1.70 after Thursday’s -$0.59);

· bluebird bio (BLUE -$1.34 after Thursday’s -$1.90 and Wednesday’s +$2.22);

Incliners:

· Alnylam Pharmaceuticals (ALNY +$3.52);

· Aduro Biotechnologies (ADRO +$0.345);

· MiMedx (MDXG +$0.29);

· Ultragenyx (RARE +$0.10 after Thursday’s +$0.65);

· Caladrius Biosciences (CLBS +$0.03);

The percentage (%) indicators:

· Friday’s range of the 9 upside was +0.06% (CLLS) to +13.66% (ADRO) while the 26 downside ranged from -0.43% (BLFS) to -12.43% (AGTC);

· Thursday’s range of the 12 upside was +0.30% (ALNY) to +756.86% (BLCM – on reverse) while the 23 downside ranged from -0.29% (VCEL) to -18.54% (AGTC);

· Wednesday’s range of the 27 upside was +0.56% (BLFS) to +22.77% (ADRO) while the 5 downside ranged from -0.02% (IONS) to -17.81% (BLCM);

· Tuesday’s range of the 30 upside was +0.51% (PSTI) to +20.43% (ADRO) while the 5 downside ranged from -0.18% (SAGE) to -6.78% (CLBS);

· Monday’s range of the 24 upside was +0.21% (IONS) to +11.48% (BLCM) while the 8 downside ranged from -0.13% (ALNY) to -5.17% (RENE.L);

Upside volume stats: to compare

· Friday: 2 out of the 9 upside had higher than the 3-month average volume;

· Thursday: 4 out of the 12 upside had higher than the 3-month average volume;

· Wednesday: 4 out of the 27 upside had higher than the 3-month average volume;

· Tuesday: 7 out of the 30 upside had higher than the 3-month average volume;

· Monday: 4 out of the 24 upside had higher than the 3-month average volume;

Downside volume stats:

· Friday: 2 out of the 26 downside had higher than the 3-month average volume;

· Thursday: 4 out of the 23 downside had higher than the 3-month average volume;

· Wednesday: 1 out of the 5 downside had higher than the 3-month average volume;

· Tuesday: 1 out of the 5 downside had higher than the 3-month average volume;

· Monday: 1 out of the 8 downside had higher than the 3-month average volume;

0 flats

February

Friday closed negative with 26 decliners, 9 advancers and 0 flat

Thursday closed negative with 23 decliners, 12 advancers and 0 flat

Wednesday closed positive with 5 decliners, 27 advancers and 3 flats

Tuesday closed positive with 5 decliners, 30 advancers and 0 flats

Monday (2/3) closed positive with 8 decliners, 24 advancers and 3 flats

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.